Loading organizations...
§ Venture Capital · Boston, MA, USA
Global biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases and cancer, focused on immune modulation.
argenx is a global biopharmaceutical company based in Ghent, Belgium, that discovers, develops, and commercializes targeted antibody-based therapies for severe autoimmune diseases and cancer. The enterprise utilizes its proprietary SIMPLE Antibody platform, derived from the immune systems of llamas, to engineer treatments that modulate the human immune system. Generating revenue through direct product sales and strategic licensing agreements with pharmaceutical partners like Shire, the firm operates across subsidiaries in Europe and the United States. Publicly traded on the NASDAQ and Euronext Brussels, the organization maintains a market capitalization exceeding $25 billion and employs approximately 1,800 people worldwide. Following regulatory approval from the FDA, the company achieved $1.19 billion in global net product sales during 2023 for its flagship immunology medication, Vyvgart. argenx was founded in 2008 by Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier.
argenx has raised $93.6M across 5 funding rounds.
Key people at argenx.
argenx was founded in 2008 by Tim Van Hauwermeiren (Founder and CEO).
argenx has raised $93.6M in total across 5 funding rounds.
Key people at argenx.
argenx has raised $93.6M across 5 funding rounds. Most recently, it raised $34.0M Other Equity in June 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 16, 2026 | Unnatural Products | $45.0M Series B | Nicholas Shekerdemian | Droia Ventures, First Spark Ventures, Merck |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 3, 2016 | $34M Venture Round | — | Aquilo Capital, Burrage Capital, Dafna Capital, MPM Capital, Perceptive Advisors | Announced |
| Nov 6, 2013 | $6.8M Series B Plus | Chris DE Jonghe | — | Announced |
| Dec 1, 2011 | $37.1M Series B | Michael B. Sheffery, Isabelle DE Cremoux | BioGeneration Ventures, Credit Agricole Private Equity, Erasmus Biomedical Fund, Forbion, LSP, Thuja Capital, VIB | Announced |
| Nov 3, 2009 | $1.9M Grant | Institute For The Promotion OF Innovation BY Science And Technology IN Flanders | — | Announced |
| Sep 10, 2009 | $13.8M Series A | Forbion, LSP | BioGeneration Ventures, Erasmus MC O&O Holdings, KBC, Thuja Capital | Announced |
argenx was founded in 2008 by Tim Van Hauwermeiren (Founder and CEO).
argenx has raised $93.6M in total across 5 funding rounds.
argenx's investors include Aquilo Capital, Burrage Capital, Dafna Capital, MPM Capital, Perceptive Advisors, Chris De Jonghe, Michael B. Sheffery, Isabelle de Cremoux, BioGeneration Ventures, Credit Agricole Private Equity, Erasmus Biomedical Fund, Forbion.
